Merck Suspends Enrollment In Phase II Trial Of Vertex Leukemia Drug Due To Heart Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial that initiated in December aimed to enroll 270 adult patients, Merck tells “The Pink Sheet” DAILY. Those already enrolled may continue treatment pending a safety review.